For instance, should breast cancer recur in the patient from which PDX-BCX1 and tamoxifen-resistant sublines were derived; our progress in NSG-Pro mice predicts that PARP plus LIG3 inhibitors would be effective. This evidence concerns the gene LIG3 and breast cancer.